ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

4:30PM-6:00PM
Abstract Number: 1871
Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes
4:30PM-6:00PM
Abstract Number: 1857
If Mobile Advertising Is the Future, the Future Is Now:  Productivity of Digital Ads By Terminology and Delivery Device.
ARHP Education/Community Programs
4:30PM-6:00PM
Abstract Number: 1896
IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders
Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases
4:30PM-6:00PM
Abstract Number: 1911
Impaired Control of Autoreactive T Cell Expansion Is Coupled with Type-1 Regulatory T Cell Deficiency in BALB/c ZAP70W163C Mutant Mice
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology
4:30PM-6:00PM
Abstract Number: 1863
Inflammatory Dietary Pattern and Risk of Developing Rheumatoid Arthritis in Women
ACR/ARHP Combined: Epidemiology and Public Health: Prevention, Recognition, and Treatment
4:30PM-6:00PM
Abstract Number: 1913
Inter-Omic Analysis Reveals Functional Relationship between Diverse Gut Microbiota and Dysregulated Host Immune Response in HLA-B27-Mediated Experimental Spondyloarthritis
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology
4:30PM-6:00PM
Abstract Number: 1909
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy
4:30PM-6:00PM
Abstract Number: 1908
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy
4:30PM-6:00PM
Abstract Number: 1864
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
ACR/ARHP Combined: Epidemiology and Public Health: Prevention, Recognition, and Treatment
4:30PM-6:00PM
Abstract Number: 1891
Low Alkaline Phosphatase Levels: Could It be Hypophosphatasia?
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis
4:30PM-6:00PM
Abstract Number: 1879
Majority of Rheumatoid Arthritis Patients in Clinical Remission As Defined By DAS-28, CDAI, SDAI and RAPID-3 Have No Signal on Ultrasound Power Doppler
Imaging of Rheumatic Diseases I: Novel Imaging and Scoring Systems
4:30PM-6:00PM
Abstract Number: 1859
Meeting the Needs of Rheumatology Health Professional Learners:  the Success of the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Online Educational Products
ARHP Education/Community Programs
4:30PM-6:00PM
Abstract Number: 1884
Mepolizumab for the Treatment of Patients with Eosinophilic Granulomatosis with Polyangiitis: Post-Hoc Results of a Phase III Randomized, Placebo-Controlled Trial
Miscellaneous Rheumatic and Inflammatory Diseases I
4:30PM-6:00PM
Abstract Number: 1865
Novel Approach to Arthritis Surveillance Suggests a Much Higher Prevalence of Arthritis Among US Adults Than Previous Estimate
ACR/ARHP Combined: Epidemiology and Public Health: Prevention, Recognition, and Treatment
4:30PM-6:00PM
Abstract Number: 1899
Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Rheumatoid Arthritis – Clinical Aspects III: Obesity and Other Comorbidities
  • «Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology